Biotech Platform Benchling Valued at $6.1 Billion in New Funding
- New investor Franklin Templeton leads round with Altimeter
- Companies using firm’s software include Regeneron, Eli Lilly
This article is for subscribers only.
Benchling, a maker of software for the biotechnology industry, is valued at $6.1 billion after a funding round led by Altimeter Capital Management and new investor Franklin Templeton.
The San Francisco-based startup raised $100 million in a Series F round that also included new investors Tiger Global Management and Lone Pine Capital, according to statement reviewed by Bloomberg News. Benchling was last valued at $4 billion in an April fundraising led by Sequoia.